Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents

Epilepsy Research

Volumn 63, Issue 1, 2005, Pages 17-25

  Danielsson, Bengt R ^a   Lansdell, Kate ^b   Patmore, Leslie ^b   Tomson, Torbjörn ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

hERG; IKr; Lamotrigine; Sudden death; Topiramate and gabapentin

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; TOPIRAMATE;

ARRHYTHMOGENESIS; ARTICLE; CELL STRAIN HEK293; DRUG EFFECT; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; IC 50; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

EID: 13544263591     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2004.10.002     Document Type: Article

References (37)

1. J.F. Annegers, and S.P. Coan SUDEP overview of definitions and review of incidence data Seizure 8 1999 347 352
2. H. Askmark, and M. Pettersson Fatal adverse reactions to antiepileptic drugs, as seen in a spontaneous reporting system S.I. Johannessen T. Tomson M. Sillanpää B. Pedersen Medical Risks in Epilepsy 2001 Wrightson Biomedicine Publication Ltd. Petersfield, Philadelphia 79 94
3. Canadian Minister of Health, 2001. Therapeutic Products Directorate Guidance Document: Assessment of the QT Prolongation Potential of Non-antiarhytmic Drugs. Canadian Minister of Health. Ref Type: Internet Communication.
4. M.E. Curran, I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, and M.T. Keating A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome Cell 80 1995 795 803
5. B.R. Danielsson, K. Lansdell, L. Patmoore, and T. Tomson Phenytoin and phenobarbital inhibit human hERG potassium channels Epilepsy Res. 55 2003 147 157
6. EMEA, 1997. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardivascular Medicinal Products (EMEACPMP/986/96). Internet.
7. D.M. Ficker, E.L. So, W.K. Shen, J.F. Annegers, P.C. O'Brien, G.D. Cascino, and P.G. Belau Population-based study of the incidence of sudden unexplained death in epilepsy Neurology 51 1998 1270 1274
8. H. Grunze, J.v. Wegerer, R.W. Greene, and J. Walden Modulation of calcium and potassium currents by lamotrigine Neuropsychobiology 38 1998 131 138
9. J.C. Hancox, and H.J. Witchel Psychotropic drugs, hERG, and the heart Lancet 356 2000 428
10. C.-W. Hunag, C.-C. Huang, Y.-C. Liu, and S.-N. Wu Inhibitory effect of lamotrigine on A-type potassium current in hippocampal neuron-derived H19-7 cells Epilepsia 45 2004 729 736
11. ICH, 2003. ICHS7B: Nonclinical Studies for Assessing Risk of Cardiac Arrhythmia Associated with Delayed Ventricular Repolarization (QT Interval Prolongation) for Human Pharmaceuticals. Step 2. Ref Type: Internet Communication.
12. S.I. Johannessen, D. Battino, D.J. Berry, M. Bialer, G. Kramer, T. Tomson, and P.N. Patsalos Therapeutic drug monitoring of the newer antiepileptic drugs Ther. Drug Monitor. 25 2003 347 363
13. Y. Langan, L. Nashef, and J.W. Sander Sudden unexpected death in epilepsy: a series of witnessed deaths J. Neurol. Neurosurg. Psychiatry 68 2000 211 213
14. J.E. Leestma, J.F. Annegers, M.J. Brodie, S. Brown, P. Schraeder, D. Siscovick, B.B. Wannamaker, P.S. Tennis, M.A. Cierpial, and N.L. Earl Sudden unexplained death in epilepsy: observations from a large clinical development program Epilepsia 38 1997 47 55
15. M. Malik, and A.J. Camm Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Saf. 24 2001 323 351
16. + channel by the gastrointestinal prokinetic agent cisapride Am. J. Physiol. 273 1997 H2534 H2538
17. L. Nashef, F. Walker, P. Allen, J.W. Sander, S.D. Shorvon, and D.R. Fish Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy J. Neurol. Neurosurg. Psychiatry 60 1996 297 300
18. L. Nilsson, U. Bergman, V. Diwan, B.Y. Farahmand, P.G. Persson, and T. Tomson Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study Epilepsia 42 2001 667 673
19. L. Nilsson, B.Y. Farahmand, P.G. Persson, I. Thiblin, and T. Tomson Risk factors for sudden unexpected death in epilepsy: a case-control study Lancet 353 1999 888 893
20. K. Opeskin, A.S. Harvey, S.M. Cordner, and S.F. Berkovic Sudden unexpected death in epilepsy in Victoria J. Clin. Neurosci. 7 2000 34 37
21. C.E. Orringer, J.C. Eustace, C.D. Wunsch, and L.B. Gardner Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia N. Engl. J. Med. 297 1977 796 799
22. T.A. Pedley, and W.A. Hauser Sudden death in epilepsy: a wake-up call for management Lancet 359 2002 1790 1791
23. M.G. Pricone, C.V. King, O.H. Drummer, K. Opeskin, and I.M. McIntyre Postmortem investigation of lamotrigine concentrations J. Forensic Sci. 45 2000 11 15
24. J.A. Racoosin, J. Feeney, Burkhart, and G. Boehm Mortality in antiepileptic drug programs Neurology 56 2001 514 519
25. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palthorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs; evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
26. P. Tennis, T.B. Cole, J.F. Annegers, J.E. Leestma, M. McNutt, and A. Rajput Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada Epilepsia 36 1995 29 36
27. M. Thom, S. Seetah, S. Sisodiya, M. Koepp, and F. Scaravilli Sudden unexpected death in epilepsy (SUDEP): evidence of acute neuronal injury using HSP-70 and c-Jun immunohistochemistry Neuropathol. Appl. Neurobiol. 29 2003 132 143
28. T. Tomson, E. Beghi, A. Sundqvist, and S.I. Johannessen Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention Epilepsy Res. 60 2004 1 16
29. M.C. Trudeau, J.W. Warmke, B. Ganetzky, and G.A. Robertson hERG, a human inward rectifier in the voltage-gated potassium channel family Science 269 1995 92 95
30. + current in cardiac ventricular myocytes Pflugers Arch. 439 2000 739 751
31. S. Viskin Long QT syndromes and torsade de pointes Lancet 354 1999 1625 1633
32. T.S. Walczak, I.E. Leppik, M. D'Amelio, J. Rarick, E. So, P. Ahman, K. Ruggles, G.D. Cascino, J.F. Annegers, and W.A. Hauser Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study Neurology 56 2001 519 525
33. T.S. Walczak Do antiepileptic drugs play a role in suddden unexpected death in epilepsy? Drug Saf. 26 2003 673 683
34. R. Webster, D. Leishman, and D. Walker Towards a drug concentration effect relationship for QT prolongation and torsades de point Curr. Opin. Drug Discovery Dev. 1 2002 116 128
35. H.J. Witchel, and J.C. Hancox Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current Clin. Exp. Pharmacol. Physiol. 27 2000 753 766
36. I.C.K. Wong, G.E. Mawer, and J.W.A.S. Sander Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom Epilepsia 42 2001 237 244
37. Z. Zhou, Q. Gong, B. Ye, Z. Fan, J.C. Makielski, G.A. Robertson, and C.T. January Properties of hERG channels stably expressed in HEK 293 cells studied at physiological temperature Biophys. J. 74 1998 230 241